Deals Of The Week: NewDrugs4BadBugs Initiative, GSK/Auxilium, DaVita/Healthcare Partners
You may also be interested in...
The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.
Sanofi Continues Search For Novel Compounds In Asia, Inking Deal With India's Glenmark For Phase I Biologic
Deal is first for a biological candidate from India.
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India